Changes in the Distribution of Capsular Serotypes of Streptococcus Pneumoniae Isolated from Adult Respiratory Specimens in Japan
Total Page:16
File Type:pdf, Size:1020Kb
□ ORIGINAL ARTICLE □ Changes in the Distribution of Capsular Serotypes of Streptococcus pneumoniae Isolated from Adult Respiratory Specimens in Japan Hisashi Shoji 1, Masayuki Maeda 2, Tetsuro Shirakura 3, Takahiro Takuma 1, Hideaki Hanaki 4 and Yoshihito Niki 1 Abstract Objective The objective of this study was to assess whether the distribution of pneumococcal capsular types has been changed, while also providing basic data on changes in the distribution after the introduction of Pneumococcal conjugated vaccine (PCV)13 in adult medical practice. Methods We analyzed 431 Streptococcus pneumoniae strains (200 in 2006 and 231 in 2012) that had been isolated from respiratory infection specimens from adult patients. Capsular typing was performed by the Quellung reaction and multiplex polymerase chain reaction. Results A comparison of the 2006 and 2012 strains revealed that the number and proportion of strains by serotype increased from 30 (15%) to 46 (20%) for serotype 3, from 4 (2%) to 14 (6%) for serotype 6A, and from 4 (2%) to 13 (6%) for serotype 6C, whereas the number and proportion of strains by serotype de- creased from 8 (4%) to 0 (0%) for serotype 4 and from 24 (12%) to 17 (7%) for serotype 6B. From 2006 to 2012, the coverage rate significantly decreased from 39 to 28.1% for PCV7 (p=0.017). Conclusion Our study showed a decrease in the vaccine coverage of PCV7. However, PCV13 covered se- rotypes 3 and 6A, which are prevalent, as well as penicillin-resistant S. pneumoniae strains. At present, PCV 13 in adult clinical practice seems to be highly significant. However, there is a possibility that the distribution has changed, and careful screening should be continued in the future. Key words: Streptococcus pneumoniae, pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, community-acquired pneumonia, invasive pneumococcal disease (Intern Med 54: 1337-1341, 2015) (DOI: 10.2169/internalmedicine.54.3845) slow development of new antimicrobial agents. There are no Introduction practical solutions to address these factors. Pneumococcus is the most important pathogen causing adult respiratory infec- Despite remarkable progress in the clinical practice for tions (1). S. pneumoniae is a gram-positive bacterial patho- pneumonia, the disease remains the third leading cause of gen that causes respiratory and otolaryngological infections death in Japan. Mortality due to pneumonia is particularly such as pneumonia, tympanitis and sinusitis. It also causes increasing rapidly amongst the elderly. The most important serious invasive diseases such as meningitis and septicemia factor related to this phenomenon is the aging of society. in all age groups. Pneumococcal strains are covered by Other possible factors include inflation in medical costs, an polysaccharide capsules, and the capsules are closely related increasing number of antimicrobial-resistant bacteria, and to pathogenicity. These capsules serve as a barrier to prevent 1Division of Clinical Infectious Diseases, Department of Medicine, School of Medicine, Showa University, Japan, 2Division of Infection Control Sciences, Department of Pharmacotherapeutics, School of Pharmacy, Showa University, Japan, 3Department of Microbiology, School of Medi- cine, Showa University, Japan and 4Research Center for Infections and Antimicrobials, Kitasato Institute for Life Science, Kitasato University, Japan Received for publication September 24, 2014; Accepted for publication January 4, 2015 Correspondence to Dr. Hisashi Shoji, [email protected] 1337 Intern Med 54: 1337-1341, 2015 DOI: 10.2169/internalmedicine.54.3845 Table 1. The Detail of Specimens in this Study Each Year. points of 2006 and 2012. The study is aimed to assess Year whether the distribution has been changed and also to pro- Characteristics 2006 2012 vide basic data to assess changes in the distribution after the Number of specimens 200 241 introduction of PCV13 in adult medical practice. Participation number of facilities 35 39 Kind of specimens Sputum 190(95.0%) 199(86.1%) Materials and Methods Specimens of trans-tracheal aspiration 6(3.0%) 24(10.4%) Specimens of bronchoscopy 2(1.0%) 6(2.6%) Others 2(1.0%) 2(0.9%) Streptococcus pneumoniae strains Patient backgrounds Age, Median (interquartile range) 72(62-80) 72(63-79) In this study, we obtained 200 and 231 Streptococcus Sex pneumoniae strains from a Japanese surveillance in 2006 Men 142(71.0%) 153(66.2%)* Female 58(29.0%) 76(32.9%)* and 2012, respectively. The surveillance was nationwide and Diagnosis conducted by the Japanese Society of Chemotherapy, the Community-acquired pneumonia 124(62.0%) 162(70.1%) Japanese Association for Infectious Diseases and the Japa- Hospital-acquired pneumonia 26(13.0%) 19(8.2%) Acute Exacerbation of Chronic Bronchitis 27(13.5%) 24(10.4%) nese Society of Clinical Microbiology (6). The strains of Others 23(11.5%) 26(11.3%) well-diagnosed adult respiratory tract infection were isolated Susceptibility from the sputum and specimens of the trans-tracheal aspira- Penicillin-susceptible S. pneumoniae 122(61.0%) 146(63.2%)* Penicillin-intermediate S. pneumoniae 70(35.0%) 73(31.6%)* tion or bronchoscopy (1, 6). Their causality was confirmed Penicillin-resistant S. pneumoniae 8(4.0%) 11(4.8%)* by quantitative culture, Gram staining, and observation of * lack of data phagocytes (1, 6). Table 1 shows the participation number of institutes, patient backgrounds and kind of specimens. All strains were grown on Sheep Blood AgarⓇ (Nippon human complement involved in the opsonization from at- Beckton-Dickinson, Tokyo, Japan) and maintained at 35℃ TM taching to the bacterial surface. This function gives the bac- with 5% CO2. The strains were stored in a Microbank sys- teria strong power to resist phagocytosis by human polymor- tem (IWAKI, Tokyo, Japan) at -80℃. phonuclear leukocytes. The capsule thus constitutes the prin- Susceptibility testing cipal cause of the strong pathogenicity of pneumococcal strains. At present, 93 different types of pneumococcal cap- The bacterial susceptibility to penicillin G (PCG) was sule have been identified (2). studied using the broth microdilution method. The reference Preventive measures against pneumococcal infections are broth microdilution method was performed according to the important for carriers who are at a high risk for death due to Clinical Laboratory Standard Institution guidelines (7). The an immunocompromised condition associated with antican- test medium was prepared using cation-adjusted Mueller- cer agents, corticosteroids, and/or biologicals, human immu- Hinton broth (Eikenkagaku, Tokyo, Japan) with lysed horse nodeficiency virus infection or acquired immunodeficiency blood (Nippon Biotest Laboratory, Tokyo, Japan). Microtiter syndrome. Pneumococcal vaccination is an effective preven- plates were then inoculated to produce a final inoculum den- tive method against pneumococcal infections. Pneumococcal sity of approximately 5×105 colony forming unit (CFU)/mL, vaccines are classified into two categories, namely, pneumo- which was regularly controlled by counting the colonies. coccal polysaccharide vaccine (PPV) and pneumococcal The inoculated plates were incubated at 36℃ for 20-24 h conjugate vaccine (PCV). Pneumococcal conjugate vaccine, before interpreting the results. Minimum inhibitory consen- showing higher immunogenicity than PPV, is mainly used in tration (MIC) was defined as the lowest concentration of an- children (3). In the pediatric field, children have been immu- tibiotics that inhibited bacterial growth. Strains with PCG nized with PCV7, which contains seven types of capsular MIC !0.06 μg/mL were classified as penicillin-susceptible S. antigen, since 2010 and PCV13, which contains 13 types, pneumoniae (PSSP), those with PCG MIC of 0.12 to 1 μg/ since 2013. The efficacy of PCV7 has been demonstrated in mL as penicillin-intermediate S. pneumoniae (PISP), and the United States, as represented by a significant reduction those with PCG MIC "2 μg/mL as penicillin-resistant S. in invasive pneumococcal diseases (IPDs) (4). pneumoniae (PRSP). In Japan, where pneumococcal polysaccharide vaccine 23 Capsular typing (PPV23) containing 23 types of capsular antigen has been conventionally given to adults, PCV13 has become available Capsular typing was performed by the Quellung reaction for adult use since June 2014. In the pediatric field, it has and multiplex polymerase chain reaction (PCR). The Quel- been reported that vaccine coverage rates decreased in asso- lung reaction was performed using a set of antisera obtained ciation with the changes in the distribution of capsular types from Statens Serum Institute (Copenhagen, Denmark). The after the introduction of the new vaccines (5). We herein re- typing procedure was performed as described in the previous port a study of the distribution of capsular serotypes of report (8). The multiplex PCR was performed based on the Streptococcus pneumoniae in the field of adult respiratory procedure of the Streptococcus Laboratory in the Center for infections in Japan, including analysis at the two assessment Disease Control and Prevention (9). The PCRs were per- 1338 Intern Med 54: 1337-1341, 2015 DOI: 10.2169/internalmedicine.54.3845 50 45 (n = 200) 40 35 PSSP PISP PRSP 30 25 20 15 10 5 0 4 3 1 7F 31 34 14 13 37 6C 7C 6B 9V 9A 6A 6D NT 9N 24F 19F 23F 22F 16F 15C 18C 15B 35B 11A 10A 15A 23A 19A PCV7 38/25A Group9 24A/24B PCV13 Group33 PPV23 29orGroup35 Figure 1. Distribution of serogroups/types amongst 200 Streptococcus pneumoniae isolated from adult patients with respiratory infections in 2006. PSSP: penicillin-susceptible S. pneumoniae, PISP: penicillin-intermediate S. pneumoniae, PRSP: penicillin-resistant S. pneumoniae 50 (n = 231) 45 40 35 PSSP PISP PRSP 30 25 20 15 10 5 0 1 4 3 7F 31 34 37 13 14 7C 6C 6B 9V 9A 6A 6D NT 9N 24F 16F 22F 19F 23F 15C 18C 35B 15B 15A 23A 11A 10A PCV719A 38/25A Group9 24A/24B PCV13 Group33 PPV23 29orGroup35 Figure 2. Distribution of serogroups/types amongst 231 Streptococcus pneumoniae isolated from adult patients with respiratory infections in 2012. PSSP: penicillin-susceptible S. pneumoniae, PISP: penicillin-intermediate S. pneumoniae, PRSP: penicillin-resistant S.